Sanofi Trades Legacy Portfolio for Equity Stake: Strategic Pruning or Value Concession?

Sanofi Forms Strategic Partnership with Cheplapharm for Mature Medicines

Sanofi and Cheplapharm have announced a strategic partnership where Sanofi will divest a selection of 20 mature medicines and three manufacturing sites to Cheplapharm. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm. This collaboration, building on a relationship initiated in 2014, aims to allow Sanofi to focus on innovative medicines while Cheplapharm leverages its specialized expertise to manage the lifecycle of these established products. The commercial transfer is slated to begin in Q1 2027, with full transaction completion expected by Q3 2027.

• Sanofi is transferring a portfolio of 20 mature medicines, including the flagship product Lovenox®/Clexane® (enoxaparin) (excluding the US market), along with three manufacturing sites located in Csanyikvölgy, Hungary (c.400 employees), Jurong, Singapore (c.100 employees), and Ploërmel, France (c.65 employees). In exchange, Sanofi will acquire a 26.4% equity stake in Cheplapharm.
• The partnership is designed to enable Sanofi to intensify its focus on R&D and innovative medicines, while ensuring that mature, essential medicines continue to meet patient needs under Cheplapharm's specialized management. This model recognizes the distinct operational requirements for innovative versus established pharmaceutical products.
• The commercial transfer of the medicine portfolio is scheduled to commence in the first quarter of 2027, followed by the transfer of the manufacturing sites. The entire transaction is anticipated to be fully completed by the third quarter of 2027, with existing employment arrangements and supply continuity maintained throughout the transition.

Lovenox/Clexane: A Mature Medicine with a Known Safety Profile

Published literature on enoxaparin spans multiple clinical settings — from orthopedic surgery and neuraxial anesthesia to pregnancy, mechanical heart valves, and oncology — and collectively documents a safety profile defined by a consistent set of hemorrhagic and hematologic risks that vary meaningfully by patient population and procedural context.

• Hemorrhagic complications in neuraxial procedures: Spinal epidural hematoma is a rare but serious neurological complication associated with enoxaparin use in the perioperative period. Cases have been reported even when anticoagulation guidelines — including those of the American Society for Regional Anesthesia and Pain Medicine regarding withholding and reintroducing warfarin and enoxaparin — were strictly followed. Published case series identify specific patient-level risk factors as contributors to hemorrhagic events, and early MRI diagnosis followed by surgical decompression is described as the standard treatment. Delayed diagnosis is associated with permanent neurological sequelae.

• Bleeding risk in bridging therapy: In a prospective registry of 116 patients with mechanical heart valves undergoing periprocedural interruption of oral anticoagulation, bridging with enoxaparin resulted in no thromboembolic events (95% CI 0–3.1%) but one major bleeding complication (0.86%; 95% CI 0.02–4.7%) and minor bleeding in 10 patients (8.6%; 95% CI 4.2–15.3%). Hemorrhages arose after a mean of 5.4 ± 1.4 days of LMWH therapy, and extended duration of LMWH therapy was identified as a factor that "seems to promote the incidence of hemorrhage."

• VTE prophylaxis after total joint arthroplasty: In a nationwide database analysis of 72,670 THA patients, enoxaparin (n = 6,791) demonstrated the lowest risk for PE and DVT among the agents studied. A separate large database study in TKA patients found enoxaparin associated with a DVT incidence of 3.5% and PE incidence of 1.1% at 90 days, along with a blood transfusion rate of 13% — higher than aspirin (7%) and factor Xa inhibitors (9%). A retrospective THA study (n = 2,107) reported gastrointestinal bleeding in 0.49% (1/202) of the enoxaparin group versus 0.05% (1/1,905) in the aspirin group, and a fatal PE rate of 0.49% (1/202) versus 0.05% (1/1,905) for aspirin.

• Heparin-induced thrombocytopenia (HIT): Enoxaparin exposure has been documented as a trigger for HIT, a paradoxical prothrombotic syndrome mediated by antibodies directed to complexes of LMWH and platelet factor 4 (PF4). One published case described a "catastrophic HIT" following enoxaparin use after knee replacement, involving arterial and venous cerebral, pulmonary, hepatic, and lower-limb vascular thromboses. In a separate oncology case, a positive platelet function antibody consistent with HIT led to enoxaparin discontinuation and substitution with fondaparinux, after which platelet count recovered.

• Dosing challenges in specialty populations: A case series evaluating anti-factor Xa (antiXa) monitoring in patients with renal impairment (creatinine clearance ≤ 50 ml/min), extremes of body weight, pregnancy, and pediatric patients found that patients with renal impairment and low body weight were more likely to be sub-therapeutic at the first antiXa level check. Neonates and young children required increased enoxaparin doses to achieve therapeutic antiXa levels. Optimal dosing in these populations was described as not established.

• Use in pregnancy: Among 38 pregnant women with thrombophilia risk, 27 received enoxaparin. Obstetric complications — including hypertension, preeclampsia, placenta abruptio, VTE, and oligohydramnios — occurred in 68.4% of the thrombophilia group versus 37.5% of controls (OR 3.6; 95% CI 1.42, 9.21, P < 0.001), though complications were described as lowest among patients who received full-dose anticoagulation.

Beyond Current Use: New Indications for Lovenox/Clexane

Enoxaparin (Lovenox/Clexane) is being investigated across a range of indications beyond its established uses, spanning oncology, infectious disease, obstetrics, and acute medical illness. The trials described below employ varied intervention models, from parallel-group randomized controlled trials to retrospective comparative analyses.

Where Enoxaparin Stands in the Anticoagulant Landscape

Enoxaparin (Lovenox/Clexane) is a low-molecular-weight heparin (LMWH) that exerts its anticoagulant effect primarily through indirect factor Xa inhibition. Several other agents sharing this LMWH mechanism of action — dalteparin and tinzaparin — have been investigated across overlapping indications, including venous thromboembolism (VTE) prophylaxis and treatment.

The knowledge base does not have sufficient information on this aspect.

Sanofi's Portfolio Reshaping: Fueling Future Breakthroughs

Sanofi's recent strategic partnership with Cheplapharm marks a definitive step in its ongoing transformation, signaling a clear intent to pivot aggressively towards innovative medicines and away from the lifecycle management of mature products. This divestment, encompassing 20 established medicines and three manufacturing sites, allows Sanofi to reallocate substantial resources—both financial and human—to its core R&D strengths. This strategic focus is consistent with its historical engagement in cutting-edge research, such as identifying small molecules for oligodendrocyte progenitor cell differentiation to address neurodegenerative diseases like Multiple Sclerosis. By shedding its legacy portfolio, Sanofi aims to accelerate its pipeline in areas promising higher growth and greater patient impact, potentially including advanced drug delivery systems like 3D printing for personalized pediatric formulations.

For Cheplapharm, this transaction represents a significant expansion, solidifying its market position as a specialist in managing established brands. This specialization is crucial for maintaining the integrity and stability of the pharmaceutical supply chain, ensuring that essential, non-innovative medicines remain accessible. The continued availability of legitimate, quality-controlled products is paramount, especially in light of growing concerns over counterfeit medicines that pose serious public health risks, as evidenced by fatal intoxications from substances like etonitazepyne in fake oxycodone.

However, such a large-scale transition is not without its challenges. The phased commercial transfer, extending into Q3 2027, introduces a period of potential supply chain disruption or manufacturing complexities that will require meticulous oversight to prevent patient access issues. Furthermore, while the pursuit of innovation is laudable, Sanofi is consciously foregoing the stable revenue streams generated by these mature products. This financial trade-off places increased pressure on its innovative pipeline to deliver successful, high-value assets to justify the divestment. The long-term success of this strategy hinges on Sanofi's ability to consistently bring breakthrough therapies to market, while Cheplapharm effectively manages and sustains the divested portfolio, ensuring both companies thrive in their specialized roles.